Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEMarc Humbert, K. Surrey, Richard Beasley et al.|Allergy|2004Cited by 1.1k
Evaluating the Toxicity of Airborne Particulate Matter and Nanoparticles by Measuring Oxidative Stress Potential—A Workshop Report and Consensus StatementJon G. Ayres, John R. Froines, Ken Donaldson et al.|Inhalation Toxicology|2008Cited by 615